# Regorafenib Versus Placebo to Treat Cholangiocarcinoma

> **NCT02162914** · PHASE2 · UNKNOWN · sponsor: **Erasme University Hospital** · enrollment: 66 (actual)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** Regorafenib/active
- **DRUG:** Regorafenib/placebo

## Key facts

- **NCT ID:** NCT02162914
- **Lead sponsor:** Erasme University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-03-14
- **Primary completion:** 2019-03
- **Final completion:** 2020-12
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2020-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02162914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02162914, "Regorafenib Versus Placebo to Treat Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02162914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*